2023
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner
Strine M, Cai W, Wei J, Alfajaro M, Filler R, Biering S, Sarnik S, Chow R, Patil A, Cervantes K, Collings C, DeWeirdt P, Hanna R, Schofield K, Hulme C, Konermann S, Doench J, Hsu P, Kadoch C, Yan Q, Wilen C. DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner. PLOS Biology 2023, 21: e3002097. PMID: 37310920, PMCID: PMC10263356, DOI: 10.1371/journal.pbio.3002097.Peer-Reviewed Original ResearchConceptsGenome-wide CRISPR/Cas9 screenCRISPR/Cas9 screenPathogenic human coronavirusesKinase-independent mannerRegulated kinase 1AProviral host factorNovel drug targetsMultiple cell typesDNA accessibilityHost factorsKinase functionHuman coronavirusesHost genesDistal enhancerNovel regulatorCas9 screenKinase 1AGene expressionNeuronal developmentDYRK1ADrug targetsDiverse coronavirusesProviral activityCell typesSevere acute respiratory syndrome coronavirus 2
2021
Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia
Wang E, Pineda J, Bourcier J, Stahl M, Penson A, Wakiro I, Singer M, Cui D, Erickson C, Knorr K, Stanley R, Chen X, McMillan E, Bossard C, Aifantis I, Bradley R, Abdel-Wahab O. Modulation of RNA Splicing Enhances Response to BCL2 Inhibition in Acute Myeloid Leukemia. Blood 2021, 138: 507. DOI: 10.1182/blood-2021-146373.Peer-Reviewed Original ResearchCdc2-like kinasePre-mRNA splicingRNA splicing factorsSplicing factorsRNA processingAcute myeloid leukemiaRNA splicingBCL2 inhibitionGenetic screeningPhosphorylation of splicing factorsRegulate pre-mRNA splicingModulates RNA splicingSR protein functionResistance to therapyAntiapoptotic protein Bcl-2Overcome venetoclax resistanceRNA processing factorsDrug responseAML drugsGenome-wide CRISPR/Cas9 screenEntity's Board of DirectorsDrug-gene interactionsProtein Bcl-2Treated AML cellsAnti-apoptotic factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply